Clinical Trials Logo

Arthritis, Psoriatic clinical trials

View clinical trials related to Arthritis, Psoriatic.

Filter by:

NCT ID: NCT05071664 Active, not recruiting - Clinical trials for Arthritis, Psoriatic

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

AFFINITY
Start date: October 25, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.

NCT ID: NCT05055934 Recruiting - Psoriatic Arthritis Clinical Trials

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

Start date: October 22, 2021
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical study, consisting of a 4-week screening period, a 12-week core treatment period, a 12-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 111 adult subjects with psoriatic arthritis.

NCT ID: NCT05051943 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

OPALE
Start date: September 29, 2020
Phase:
Study type: Observational

The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.

NCT ID: NCT05049798 Active, not recruiting - Clinical trials for Arthritis, Psoriatic

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

PsABIOnd
Start date: August 25, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

NCT ID: NCT05046431 Completed - Psoriatic Arthritis Clinical Trials

Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Start date: May 6, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA. The study will consist of up to 4-week Screening Period, a 52-week Treatment Period, and a 8-week Safety Follow-up Period.

NCT ID: NCT05039216 Recruiting - Clinical trials for Rheumatoid Arthritis

Biobank for Inflammatory Chronic Diseases and Osteoporosis

BIOTOUL
Start date: September 13, 2021
Phase:
Study type: Observational

The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.

NCT ID: NCT05000086 Completed - Clinical trials for Arthritis, Psoriatic

A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis

Start date: June 1, 2019
Phase: Phase 4
Study type: Interventional

This study is aim to evaluate the efficacy and safety of technetium [99Tc] methylene diphosphonate (99Tc-MDP, trade name: Yunke) in the treatment of psoriatic arthritis.

NCT ID: NCT04991116 Recruiting - Psoriatic Arthritis Clinical Trials

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Start date: June 30, 2022
Phase: Phase 3
Study type: Interventional

An open label phase 3 study

NCT ID: NCT04967950 Recruiting - Psoriatic Arthritis Clinical Trials

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Start date: July 15, 2021
Phase: Phase 1
Study type: Interventional

Given the role of IL-17 in the development of entheseal-driven pathology, a therapeutic strategy aimed at blocking IL-17 would be a logical option for the treatment of enthesitis in psoriatic arthritis patients. This study will be the first randomized trial of a biologic therapy in participants with psoriatic arthritis, using imaging test.

NCT ID: NCT04957550 Enrolling by invitation - Psoriatic Arthritis Clinical Trials

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Start date: August 30, 2021
Phase: Phase 3
Study type: Interventional

This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.